MiR-30a-5p frequently downregulated in prostate cancer inhibits cell proliferation via targeting PCLAF

• Published in: Artificial cells, nanomedicine, and biotechnology Vol. 47; no. 1; pp. 278 - 289
• Main Authors: Zhao, Hu, Zhang, Wei, Lai, Xiaofeng, Zhu, Hehuan, Zhang, Shenhang, Wu, Weizhen, Wang, Shuiliang, Tang, Minying, Deng, Zhen, Tan, Jianming
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01-12-2019; Taylor & Francis Ltd; Taylor & Francis Group
• Subjects: Animals; Base Sequence; Carrier Proteins - genetics; Cell growth; Cell proliferation; Cell Proliferation - genetics; Down-Regulation; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Male; MicroRNAs; MicroRNAs - genetics; MiR-30a-5p; miRNA; PC-3 Cells; PCLAF; proliferation; Prostate cancer; Prostatic Neoplasms - pathology; Therapeutic applications; Tumors; PCLAF; MiR-30a-5p; prostate cancer; proliferation
• ISSN: 2169-1401; 2169-141X
• DOI: 10.1080/21691401.2018.1553783

MicroRNAs (miRNAs) have vastly expanded our view of RNA world in intracellular signal regulating networks. Here, we functionally characterized a normally highly expressed miRNA, miR-30a-5p (MIMAT0000087), which exhibits downregulated expression profiles in prostate cancer samples. MiR-30a-5p knockdown and overexpression in PC-3 cell line alters cell proliferation supporting a tumour suppressor role. We also discovered that PCLAF is the direct target of miR-30a-5p. Notably, PC-3 cell proliferation is inhibited by miR-30a-5p/PCLAF axis. miR-30a-5p represents a novel molecule of functionally important miRNAs which may shed light on the novel therapeutic targets for prostate cancer.